Custom Antibody Market by Type (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies), Service (Antibody Development, Antibody Fragmentation & Labeling, Antibody Production & Purification), Source, Research Area, End Users, Application - G

Custom Antibody Market by Type (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies), Service (Antibody Development, Antibody Fragmentation & Labeling, Antibody Production & Purification), Source, Research Area, End Users, Application - G

The Custom Antibody Market size was estimated at USD 755.86 million in 2023 and expected to reach USD 871.88 million in 2024, at a CAGR 16.10% to reach USD 2,149.90 million by 2030.

Custom antibodies are specialized proteins designed and produced to bind specifically to a single target molecule, known as an antigen. These antibodies are tailor-made to recognize and bind with high specificity to unique sites on target molecules, making them valuable tools in research, diagnostic, and therapeutic applications. The custom production of antibodies allows researchers to generate specific reagents for novel or less-studied targets or to create antibodies with desired properties that are not available off the shelf. The high prevalence and incidences of chronic and infectious diseases worldwide necessitate the development of novel diagnostic and therapeutic antibodies. Heightened investment in research and development by biopharmaceutical companies and academic institutions boosts the proliferation of custom antibodies. However, the intricate processes involved in custom antibody production can be cost-intensive, and stringent regulatory requirements for antibody therapeutics can delay market entry and increase development costs. Moreover, generating antibodies with high specificity and affinity remains challenging, impacting the effectiveness of custom antibody applications. However, key players are exploring the integration of AI/ML algorithms and robotics technologies to ease the process of antibody discovery and design. Furthermore, the development of more efficient hybridoma technology and recombinant antibody production and expanding applications in targeted drug delivery systems and diagnostic imaging could also benefit the growth of the industry.

Regional Insights

The Americas, particularly the U.S. and Canada, are known for their robust research environments, contributing significantly to the demand for custom antibodies. The region's strong biotechnology and pharmaceutical sectors drive this need, with both academic and commercial labs seeking high-quality, specific antibodies for therapeutic and diagnostic applications. Recent patents in the U.S. indicate a focus on novel cancer biomarkers and neurodegenerative diseases, highlighting the ongoing innovation in antibody development. European Union (EU) countries boast advanced healthcare systems and strong regulatory support for biotechnology research, fostering a conducive environment for custom antibody development. The presence of stringent regulations for therapeutics and diagnostics molecules in the EU provides a standardized and secure framework for the progression of custom antibodies. Recent EU investments focus on combating infectious diseases and addressing chronic conditions, such as autoimmune disorders, through innovative antibody solutions. The APAC region has emerged as a pivotal landscape in the custom antibody market, supported by several government-funded initiatives to advance the healthcare infrastructure and provide marginalized communities access to diagnostics and therapeutic capabilities. China's focus on biotechnology innovation and government investments in genomics and proteomics research is creating a need for highly specialized antibodies. Japan's well-established pharmaceutical industry prioritizes precision medicine, and India's burgeoning biotechnology sector, coupled with its cost-effective manufacturing capabilities, has proved crucial for the growth of custom antibodies.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Custom Antibody Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Growing prevalence of chronic infectious disease worldwide
Expanding applications of custom antibody across research, diagnostics, and therapeutics
Rising adoption of advanced technologies in antibody engineering and personalized therapeutics

Market Restraints

Extensive and time consuming to develop custom antibodies

Market Opportunities

Governments and private sector strategically investments in life science and clinical research
Increase in therapeutics of antibodies and expansion of drug pipeline

Market Challenges

Presence of alternative antibodies

Market Segmentation Analysis

Type: Emerging need for monoclonal antibodies to tackle severe disease states
End Users: Expanding investments by the pharmaceutical & biotechnology companies in drug development and diagnostics

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Custom Antibody Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Custom Antibody Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Danaher to Buy Antibody Supplier Abcam for USD 5.7 Billion

Danaher Corporation has announced its plan to acquire Abcam, a key of antibodies, reagents, biomarkers, and assays based in Cambridge, England, for an estimated USD 5.7 billion in cash. This move aims to consolidate their positions within the life sciences tools and consumables sector to strengthen market presence.

Merck to Develop mAb Through USD 10.8 Billion Acquisition

Merck & Co. Inc has announced a strategic move to enhance its immunology portfolio through the acquisition of Prometheus Biosciences for USD 10.8 billion. This significant transaction paves the way for Merck to further the development of PRA023, a cutting-edge humanized monoclonal antibody (mAb) aimed at treating ulcerative colitis (UC), Crohn's disease (CD), and other autoimmune ailments. The collaboration is expected to leverage Prometheus's expertise in clinical-stage biotechnological research, driving forward the precision treatment of immune diseases.

Celltrion and Genuv Partner to Develop Novel Therapeutic Antibodies

Celltrion and Genuv have announced their joint venture into the custom antibody market, bringing together decades of collective experience and expertise. Their combined mission is to provide customers with highly tailored antibodies so they can continue to develop innovative treatments and drugs quickly and accurately, creating greater access for those who desperately seek improved healthcare solutions. By leveraging Celltrion's extensive R&D capabilities and Genuv's cutting-edge technology platforms, this partnership is perfectly poised to enter the global market and ultimately deliver more effective and affordable antibody therapies that will benefit both drug manufacturers and patients alike.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Custom Antibody Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Custom Antibody Market, highlighting leading vendors and their innovative profiles. These include Abbiotec, Inc., Abcam PLC, ABclonal, Inc., Abgenex Pvt. Ltd., Abnova Corporation, Acrobiosystems Inc., Agilent Technologies, Inc., Alta Bioscience Limited, Bio Basic Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BioChain Incorporated, Bioklone Biotech Private Limited, BioLegend, Inc. by PerkinElmer, Inc., Biosynth Ltd., Boster Biological Technology, BTL Biotechno Labs Private Limited, Capralogics, Inc., Cell Signaling Technology, Inc., CiteAb Limited, Creative Biolabs, Creative Diagnostics, CSBio (Shanghai) Ltd., Cusabio Technology LLC, Davids Biotechnologie GmbH, Elabscience, evitria AG by Atlas Antibiodies, GenScript Biotech Corporation, Imgenex India Pvt. Ltd., Innovagen AB, Inotiv, Inc., Kaneka Eurogentec S.A., Laboratory Corporation of America Holdings, Merck KGaA, Metabion International AG, MyBiosource, Inc., OriGene Technologies, Inc., Oy Medix Biochemica AB, Pacific Immunology, PhosphoSolutions, ProMab Biotechnologies, Inc., ProSci Incorporated, ProteoGenix SA, RayBiotech Life, Inc., Rockland Immunochemicals, Inc., Sino Biological, Inc., The Antibody Company, Thermo Fisher Scientific, Inc., and YenZym Antibodies, LLC.

Market Segmentation & Coverage

This research report categorizes the Custom Antibody Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Monoclonal Antibodies
Polyclonal Antibodies
Recombinant Antibodies
Service
Antibody Development
Antibody Fragmentation & Labeling
Antibody Production & Purification
Source
Mice
Rabbit
Research Area
Cardiovascular Diseases
Immunology
Infectious Diseases
Neurobiology
Oncology
Stem cells
End Users
Academic & Research Institutes
Contract Research Organizations
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Application
Research
Therapeutics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year